B-cell prolymphocytic leukemia pathophysiology: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
*[[CD23]] is negative but [[CD5]] is expressed in one third [[tumor]] cells population.<ref name="urlPathology">{{cite web |url=http://www.med-ed.virginia.edu/courses/path/innes/wcd/lympleuk.cfm |title=Pathology |format= |work= |accessdate=2009-01-31| archiveurl= http://web.archive.org/web/20090207235133/http://www.med-ed.virginia.edu/courses/path/innes/wcd/lympleuk.cfm| archivedate= 7 February 2009 <!--DASHBot-->| deadurl= no}}</ref><ref name="pmid24759024">{{cite journal |vauthors=Yi S, Li Z, Wang H, Liu W, Lyu R, Yu Z, Qi J, Qiu L |title=[The immunophenotypic characteristics of 260 patients with CD5 + B cell lymphoproliferative disorders] |language=Chinese |journal=Zhonghua Xue Ye Xue Za Zhi |volume=35 |issue=4 |pages=337–41 |date=April 2014 |pmid=24759024 |doi=10.3760/cma.j.issn.0253-2727.2014.04.019 |url=}}</ref> | *[[CD23]] is negative but [[CD5]] is expressed in one third [[tumor]] cells population.<ref name="urlPathology">{{cite web |url=http://www.med-ed.virginia.edu/courses/path/innes/wcd/lympleuk.cfm |title=Pathology |format= |work= |accessdate=2009-01-31| archiveurl= http://web.archive.org/web/20090207235133/http://www.med-ed.virginia.edu/courses/path/innes/wcd/lympleuk.cfm| archivedate= 7 February 2009 <!--DASHBot-->| deadurl= no}}</ref><ref name="pmid24759024">{{cite journal |vauthors=Yi S, Li Z, Wang H, Liu W, Lyu R, Yu Z, Qi J, Qiu L |title=[The immunophenotypic characteristics of 260 patients with CD5 + B cell lymphoproliferative disorders] |language=Chinese |journal=Zhonghua Xue Ye Xue Za Zhi |volume=35 |issue=4 |pages=337–41 |date=April 2014 |pmid=24759024 |doi=10.3760/cma.j.issn.0253-2727.2014.04.019 |url=}}</ref> | ||
*Another case was described as [[CD45]]+, [[CD19]]+, [[CD20]]+, [[CD5]]+, [[HLA-DR]]+, [[CD10]]-, [[CD23]]+/-, [[CD38]]+ and [[FMC7]]<ref name="pmid16997373">{{cite journal |author=Crisostomo RH, Fernandez JA, Caceres W |title=Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia |journal=Leuk. Res. |volume=31 |issue=5 |pages=699–701 |date=May 2007 |pmid=16997373 |doi=10.1016/j.leukres.2006.06.010 |url=http://linkinghub.elsevier.com/retrieve/pii/S0145-2126(06)00218-9}}</ref> | *Another case was described as [[CD45]]+, [[CD19]]+, [[CD20]]+, [[CD5]]+, [[HLA-DR]]+, [[CD10]]-, [[CD23]]+/-, [[CD38]]+ and [[FMC7]]<ref name="pmid16997373">{{cite journal |author=Crisostomo RH, Fernandez JA, Caceres W |title=Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia |journal=Leuk. Res. |volume=31 |issue=5 |pages=699–701 |date=May 2007 |pmid=16997373 |doi=10.1016/j.leukres.2006.06.010 |url=http://linkinghub.elsevier.com/retrieve/pii/S0145-2126(06)00218-9}}</ref> | ||
*Tumor cells express surface IgM proteins. | *[[Tumor cell|Tumor cells]] express surface [[IgM|IgM proteins]]. | ||
===Microscopic pathology=== | ===Microscopic pathology=== | ||
*The originating cell line for B-cell prolymphocytic leukemia is a mature B-cells and are medium sized cells. | *The originating cell line for [[B cell|B-cell]] [[prolymphocytic leukemia]] is a mature [[B cell|B-cells]] and are medium sized cells. | ||
*More than 50 percent of the circulating cells in the peripheral blood are prolymphocytes. | *More than 50 percent of the circulating cells in the [[peripheral blood]] are [[Prolymphocyte|prolymphocytes]]. | ||
*The nucleus is typically round or oval, and the cytoplasm is usually moderately abundant. | *The [[Cell nucleus|nucleus]] is typically round or oval, and the [[cytoplasm]] is usually moderately abundant. | ||
*Leukemic cells can be found in peripheral blood, lymph nodes, bone marrow, spleen, liver, and skin.<ref name="pmid2182602">{{cite journal |vauthors=Stone RM |title=Prolymphocytic leukemia |journal=Hematol. Oncol. Clin. North Am. |volume=4 |issue=2 |pages=457–71 |date=April 1990 |pmid=2182602 |doi= |url=}}</ref> | *[[Leukemic|Leukemic cells]] can be found in [[peripheral blood]], [[Lymph node|lymph nodes]], [[bone marrow]], [[spleen]], [[liver]], and [[skin]].<ref name="pmid2182602">{{cite journal |vauthors=Stone RM |title=Prolymphocytic leukemia |journal=Hematol. Oncol. Clin. North Am. |volume=4 |issue=2 |pages=457–71 |date=April 1990 |pmid=2182602 |doi= |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 14:37, 5 April 2019
|
B-cell prolymphocytic leukemia |
|
Differentiating B-cell prolymphocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
B-cell prolymphocytic leukemia pathophysiology On the Web |
|
American Roentgen Ray Society Images of B-cell prolymphocytic leukemia pathophysiology |
|
Directions to Hospitals Treating B-cell prolymphocytic leukemia |
|
Risk calculators and risk factors for B-cell prolymphocytic leukemia pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2],Carlos A Lopez, M.D. [3]
Overview
B-cell prolymphocytic leukemia arises from mature B-cells, which are hematologic white cells that are normally involved in the in the humoral immunity component of the adaptive immune system by secreting antibodies.
Pathophysiology
Markers
- B-cell prolymphocytic leukemia cells are positive for B cell markers such as CD19, CD20, CD22.[1]
- CD23 is negative but CD5 is expressed in one third tumor cells population.[2][3]
- Another case was described as CD45+, CD19+, CD20+, CD5+, HLA-DR+, CD10-, CD23+/-, CD38+ and FMC7[4]
- Tumor cells express surface IgM proteins.
Microscopic pathology
- The originating cell line for B-cell prolymphocytic leukemia is a mature B-cells and are medium sized cells.
- More than 50 percent of the circulating cells in the peripheral blood are prolymphocytes.
- The nucleus is typically round or oval, and the cytoplasm is usually moderately abundant.
- Leukemic cells can be found in peripheral blood, lymph nodes, bone marrow, spleen, liver, and skin.[5]
References
- ↑ Yamamoto K, Hamaguchi H, Nagata K, Shibuya H, Takeuchi H (April 1998). "Splenic irradiation for prolymphocytic leukemia: is it preferable as an initial treatment or not?". Jpn. J. Clin. Oncol. 28 (4): 267–9. doi:10.1093/jjco/28.4.267. PMID 9657013.
- ↑ "Pathology". Archived from the original on 7 February 2009. Retrieved 2009-01-31.
- ↑ Yi S, Li Z, Wang H, Liu W, Lyu R, Yu Z, Qi J, Qiu L (April 2014). "[The immunophenotypic characteristics of 260 patients with CD5 + B cell lymphoproliferative disorders]". Zhonghua Xue Ye Xue Za Zhi (in Chinese). 35 (4): 337–41. doi:10.3760/cma.j.issn.0253-2727.2014.04.019. PMID 24759024.
- ↑ Crisostomo RH, Fernandez JA, Caceres W (May 2007). "Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia". Leuk. Res. 31 (5): 699–701. doi:10.1016/j.leukres.2006.06.010. PMID 16997373.
- ↑ Stone RM (April 1990). "Prolymphocytic leukemia". Hematol. Oncol. Clin. North Am. 4 (2): 457–71. PMID 2182602.